Synopsis Around 10.9 M people are affected with COVID-19 in India, and 156 K people have died so far. Several clinical trials are being conducted to evaluate the safety and immunogenicity of vaccine candidates against SARS-CoV-2. In this regard, the following article summarizes the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine. This week’s Journal Watch summarizes the clinical trial “ Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomized controlled trial) and the persistence of immune responses from a phase 1 follow-up report ,” published as a pre-print article in MedRxiv .
Authors: Raches Ella, Siddharth Reddy, Harsh Jogdand, et al. What was the rationale for this study? A vero cell-based whole-virion inactivated SARS-CoV-2 vaccine candidate (BBV152) has been developed against SARS-CoV-2. A phase 1…
